Cellular Dynamics International Presents Annual iForum Meetings Focused on New Applications and Uses for Differentiated Human iPS Cells

Order Contact Careers Account Log In/Register Why CDI Partners & Providers Our Technology Cellular Therapy Drug Discovery Health & Nutrition Stem Cell Banking Products & Services iCell Products iCell Cardiomyocytes iCell Cardiomyocytes2 iCell Cardiac Progenitor Cells iCell Astrocytes iCell DopaNeurons iCell GABANeurons iCell GlutaNeurons iCell Motor Neurons iCell Hepatocytes 2.0 iCell Hepatoblasts iCell Skeletal Myoblasts... Read more

Results of a six-month study combining Roche’s Esbriet with nintedanib in patients with IPF presented at ERS

Basel, 13 September 2017 Results of a six-month study combining Roche’s Esbriet with nintedanib in patients with IPF presented at ERS New study combining Esbriet (pirfenidone) and nintedanib showing similar safety profile for the combination treatment to that expected for each treatment alone A second, retrospective, post-hoc, analysis suggests that treatment with Esbriet may be... Read more

Results of a six-month study combining Roche’s Esbriet with nintedanib in patients with IPF presented at ERS

Basel, 13 September 2017 Results of a six-month study combining Roche’s Esbriet with nintedanib in patients with IPF presented at ERS New study combining Esbriet (pirfenidone) and nintedanib showing similar safety profile for the combination treatment to that expected for each treatment alone A second, retrospective, post-hoc, analysis suggests that treatment with Esbriet may be... Read more

Xylem Inc. to participate in the Morgan Stanley 5th Annual Laguna Conference

RYE BROOK, N.Y.–(BUSINESS WIRE)–Sep. 7, 2017– Xylem Inc. (NYSE: XYL), a leading global water technology company dedicated to solving the world’s most challenging water issues, announced today that its President and Chief Executive Officer, Patrick Decker, and Manager of Investor Relations, Matthew Latino, will participate in group discussions at the Morgan Stanley 5th Annual Laguna... Read more

Illumina Files New Patent Infringement Suit Against Premaitha Health plc

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ:ILMN) announced today that the company has filed a new patent infringement suit against Premaitha Health plc in the High Court of Justice, Chancery Division, Patents Court in the United Kingdom. Illumina is seeking all available remedies, including damages and injunctive relief. The new suit accuses Premaitha’s IONA® Test of infringing... Read more